Monoclonal antibody specifically binding to cathepsin z, and use thereof
AssigneesNBIOs, INC., Kookmin University Industry Academy Cooperation Foundation
InventorsDae-Hee LEE, Tae Hyun KANG, Han Gil KIM
Life of this patent
Estimating the term…
Loading patent…
AssigneesNBIOs, INC., Kookmin University Industry Academy Cooperation Foundation
InventorsDae-Hee LEE, Tae Hyun KANG, Han Gil KIM
Estimating the term…
The present disclosure relates to a monoclonal antibody specifically binding to cathepsin Z, and a use thereof. The monoclonal antibody specifically binding to cathepsin Z of the present disclosure, or an antigen-binding fragment thereof specifically binds to CtsZ, and thus can inhibit in vivo tumorigenesis of cancer in which CtsZ is overexpressed, particularly, brain cancer, more particularly, mesenchymal brain cancer stem cells. Therefore, the present disclosure can be usefully used for treatment of patients with cancer in which CtsZ is overexpressed, specifically patients with mesenchymal brain cancer, more specifically patients with glioblastoma. In addition, the monoclonal antibody of the present disclosure or an antigen-binding fragment thereof, which specifically binds to cathepsin Z, allows diagnosis of cancer in which CtsZ is overexpressed, specifically brain cancer, more specifically glioblastoma.
A monoclonal antibody comprising any heavy chain variable region and light chain variable region selected from a group consisting of 1) to 9) and specifically binding to cathepsin Z, or an antigen-binding fragment thereof:
(canceled)
Dependencies are inferred from the claim text.